- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02120326
Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine (Medis)
Randomised Double-blind Evaluation of the Prophylactic Efficacy of Transcranial Direct Current Stimulation (tDCS) in Chronic Migraine
Study Overview
Status
Detailed Description
Consenting patients will report on a book, all of their migraine attack for 1 month. Then they will be randomized to the active tDCS group or sham tDCS group. Patients will have one session of tDCS per day during the first week, then one session per week for a month and finally a session every 15 days for 1 month. After tDCS sessions, patients will be followed for 3 months. Throughout their participation in the study, patients will complete their migraine record (1month of base line before tDCS, 2 months during tDCS, 3 months after tDCS).
Patients will have 5 evaluation examinations:
- The first, one before tDCS,
- The second, 1 month after the beginning of tDCS
- The third, immediately after the end of tDCS
- The fourth, 1 month after the end of tDCS
- And the last one, 3 months after the end of tDCS.
The physician responsible for conducting tDCS sessions will make the randomization via a website.
The physician in charge of the evaluation examinations will don't know the allocated treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Isere
-
Grenoble, Isere, France, 38043
- Grenoble University Hospital
-
Voiron, Isere, France, 38500
- Hospital of Voiron
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of chronic migraine for more than 1 year
- Stable treatment since 1 month
- Frequency of migraine crisis is above 8 per month during last month
- chronic migraine that has not been improved over the previous year by at least 3 different prophylactic treatments recommended and well conducted
- Patient agreeing not to try other migraine prophylactic treatment, throughout the study
- Patient's written consent
Exclusion Criteria:
- History of drug addiction, epilepsy, or severe head trauma with bone break
- History of psychiatric illness (psychosis and severe cognitive disorders) may interfere with the proper conduct of the study
- Presence of intracranial ferromagnetic material or an implanted stimulator
- Introduction of a new treatment for less than a month
- Pregnant women, parturient women, breast-feeding mother. Lack of effective contraception
- Person not understanding the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: active tDCS
|
The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp. Stimulation parameters:
|
Placebo Comparator: simulated tDCS
|
The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp. Stimulation parameters:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison of the evolution of seizure frequency between the two groups
Time Frame: Evolution of seizure frequency since base line to 3 months after the end of tDCS
|
Evolution of seizure frequency since base line to 3 months after the end of tDCS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of the evolution of seizure severity between the two groups
Time Frame: Evolution of seizure severity since base line to 3 months after the end of tDCS
|
Headache Impact Test 6 (HIT-6) questionnaire
|
Evolution of seizure severity since base line to 3 months after the end of tDCS
|
Comparison of the evolution of crisis treatment use between the two groups
Time Frame: Evolution of crisis treatment use since base line until 3 months after the end of tDCS
|
Frequency of taking crisis treatment.
After each crisis, taking crisis treatment will be noted by the patient on his migraine record book.
|
Evolution of crisis treatment use since base line until 3 months after the end of tDCS
|
Comparison of the evolution of the disease impact between the two groups
Time Frame: Evolution of the disease impact since base line to 3 months after the end of tDCS
|
Migraine Disability Assessment Scale (MIDAS) scale
|
Evolution of the disease impact since base line to 3 months after the end of tDCS
|
Comparison of the evolution of the patient satisfaction between the two groups
Time Frame: Evolution of the patient satisfaction since base line to 3 months after the end of tDCS
|
Clinical Global Impression (CGI) scale
|
Evolution of the patient satisfaction since base line to 3 months after the end of tDCS
|
Comparison of the evolution of the quality of life between the two groups
Time Frame: Evolution of the quality of life since base line until 3 months after the end of tDCS
|
Short Form 12 (SF-12) quality of life questionnaire
|
Evolution of the quality of life since base line until 3 months after the end of tDCS
|
Comparison of the evolution of anxiety and depression levels between the two groups
Time Frame: Evolution of anxiety and depression levels since base line until 3 months after the end of tDCS
|
Hospital Anxiety and Depression scale (HAD) questionnaire
|
Evolution of anxiety and depression levels since base line until 3 months after the end of tDCS
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: HODAJ Hasan, MD, University Hospital, Grenoble
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DCIC13/48
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Migraine as Defined by Criteria of International Headache Society (IHS)
-
Aalborg UniversityAalborg University Hospital; CCBR Aalborg A/S, Aalborg, DenmarkCompletedMigraine According to International Headache Society (IHS) Criteria (ICHD-II)Denmark
Clinical Trials on Transcranial direct current stimulation of the motor cortex
-
Seoul National University HospitalRusk Rehabilitation HospitalRecruitingStroke | Rehabilitation | Transcranial Direct Current Stimulation | Motor RecoveryKorea, Republic of
-
Fu Xing Hospital, Capital Medical UniversityRecruitingStroke | Upper Extremity Dysfunction | Transcranial Direct Current Stimulation | Image, BodyChina
-
Aalborg UniversityCompletedPain | Prolonged Experimental PainDenmark
-
Hospices Civils de LyonCompleted
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine Withdrawal | Tobacco AbstinenceUnited States
-
Samsung Medical CenterCompletedStrokeKorea, Republic of
-
Samsung Medical CenterCompletedStrokeKorea, Republic of
-
Boston University Charles River CampusNot yet recruiting
-
HaEmek Medical Center, IsraelRambam Health Care Campus; Technion, Israel Institute of TechnologyNot yet recruiting
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting